ROP.SW Roche Holding AG
Company Analysis
Latest News
Roche Expands Cancer Drug Partnership With Hansoh, Deal Could Top $15 Billion
Roche Holding AG has entered into a strategic collaboration and licensing agreement with China’s Hansoh Pharmaceutical to develop a portfolio of antibody-drug...
Roche Wins FDA Approval for Enspryng, First At-Home Thyroid Eye Treatment
The FDA approved Roche’s Enspryng (satralizumab) for adults with thyroid eye disease. This marks the first at-home, subcutaneous treatment option for the...
Roche Wins FDA Approval for Enspryng, First At-Home Thyroid Eye Disease Drug
Roche announced on October 16, 2026, that the U.S. Food and Drug Administration (FDA) approved Enspryng (satralizumab) to treat adults with thyroid eye disease...
🟢 Roche Holding is trading 3.09% up today amid healthcare rally after UnitedHealth's Q3 beat
Roche Holding is trading at CHF 370.90, up 3.09% at the October 14 close, as healthcare stocks rallied after UnitedHealth beat Q3 earnings expectations and...
🟢 Roche Holding is trading 3.03% up today amid sector rally after UnitedHealth earnings beat
Roche Holding is trading at CHF 370.70, up 3.03%, as healthcare shares benefit from UnitedHealth’s Q3 earnings beat and raised 2026 outlook. - Roche’s October...
Roche Licenses Rona Obesity Drug in Potential $1.16 Billion Deal
Roche has licensed an experimental obesity drug from China-based Rona Therapeutics, in a deal that could be worth up to $1.16 billion. The agreement gives...
Roche Reports Positive One-Year Phase III Data for Vision Loss Drug Vamikibart
Roche announced one-year data from its Phase III MEERKAT and SANDCAT studies. The studies evaluated vamikibart, an investigational drug for uveitic macular...
Roche Wins FDA Nod for Tecentriq in Stage III dMMR Colon Cancer
The U.S. Food and Drug Administration (FDA) approved Roche’s Tecentriq (atezolizumab) with chemotherapy as adjuvant treatment after surgery for Stage III colon...
Roche's Genentech Strikes Potential $1.27 Billion Deal for Parkinson's Therapy
Roche's Genentech unit has signed a licensing agreement with U.S. biotech firm Alector for AL050, a preclinical Parkinson's disease therapy. The deal has a...
Roche Reports Giredestrant Combo Cuts Progression Risk 44% in Breast Cancer Trial
Roche announced that results from its Phase III evERA Breast Cancer study were published in The New England Journal of Medicine. The trial evaluated...
Roche's Fenebrutinib Wins Priority FDA Review for Two MS Types
Roche said the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for fenebrutinib and granted it priority review. The application...
Roche signs $2 billion Atavistik deal, targeting metabolic and heart diseases
Roche partnered with Atavistik Bio to develop treatments for cardiovascular, renal, and metabolic diseases. The deal carries a total potential value of nearly...
Roche Sefaxersen Hits Phase 3 Goal, Eyes Accelerated Kidney Drug Approval
Roche reported positive interim results from its Phase III IMAgINATION study for sefaxersen. The trial evaluated the investigational drug in patients with IgA...
Roche Diabetes Drug Cuts Weight by 15.5%, Advancing to Phase III
Roche reported positive Phase II trial results for enicepatide in adults with type 2 diabetes and obesity. This once-weekly dual GLP-1/GIP receptor agonist met...
Roche Secures EU Approval for Susvimo, Reducing Eye Injections to Twice Yearly
The European Commission granted marketing authorization for Roche’s Susvimo to treat neovascular age-related macular degeneration (nAMD). This approval...
Roche Lunsumio beats standard therapy in Phase III lymphoma study
Roche announced its Phase III CELESTIMO study met its primary endpoint, showing a Lunsumio-based regimen significantly improves progression-free survival. The...
Roche Lung Cancer Drug Tam-Peli Cuts Death Risk by 54%
Roche Holding AG reported positive interim results from the Phase III TAISHAN-302 trial for Tam-Peli (tambotatug pelitecan). The study, conducted in China with...
🟢 Roche Holding is trading 3.14% up today
Roche Holding is trading at CHF 355.00 (+3.14%), with the catalyst still unclear. - The stock is rising despite a weaker overnight risk tone and lower U.S....
Roche Secures FDA Priority Review for Enspryng, Aiming for First MOGAD Treatment
The FDA granted Priority Review for Roche’s Enspryng (satralizumab) to treat myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). MOGAD is...
🟢 Roche Holding up 3.26% on new B-cell lymphoma trial collaboration and recent Simcere blood-cancer drug deal
Roche Holding is trading at CHF 360.60, up 3.26%, following a clinical trial collaboration agreement with Treeline Biosciences for a Phase I study in B-cell...